IMNM vs ARQT Comparison

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.